Psoriasis
Conditions
Keywords
Psoriasis, Plaque psoriasis, Stem cell, Cell therapy, Furestem, Mesenchymal stem cell, MSC, Umbilical cord blood, hUCB-MSC, UCB-MSC
Brief summary
Phase I clinical trial to evaluate safety of FURESTEM-CD Inj. in patients with moderate to severe in plaque-type psoriasis injection for 4weeks.
Detailed description
This is a phase 1, single center, randomized, open label, study of safety of FURESTEM-CD Inj. in subjects with moderate to severe plaque psoriasis. Approximately 9\ 18 subjects will be administrated FURESTEM-CD Inj. FURESTEM-CD Inj. is composed of allogeneic hUCB-MSC(human Umbilical Cord Blood derived-Mesenchymal Stem cell). hUCB-MSCs are mesenchymal stem cells from umbilical cord blood. Mesenchymal stem cells are well-known for immunosuppression, anti-inflammatory ability and capable of differentiating into a wide range of cell types. Therefore, FURSTEM-CD Inj. has huge possibility as cell therapy products for plaque-type Psoriasis patients.
Interventions
BIOLOGICALFURESTEM-CD Inj.
Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
Sponsors
Kang Stem Biotech Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. 19-65 years old(both sexes) 2. Have been diagnosed with plaque-type psoriasis at least 6 months prior to screening (subjects with concurrent psoriatic arthritis\[PsA\] may be enrolled) 3. Psoriasis Area and Severity Index (PASI) score \>= 12 at screening 4. BSA(Body Surface Area) \>= 10 percentage at screening 5. Have had at least one of the following conventional systemic agent for the treatment of psoriasis, * MTX, Cyclosporine, Photochemotherapy, TNF-alpha inhibitor or IL-12/IL-23 inhibitor 6. Subject who would agree to avoid prolonged sun exposure, use of tanning booths or other ultraviolet light sources during the clinical study 7. Subject who understands and voluntarily signs the informed consent form
Exclusion criteria
1. Subject who has other types of psoriasis (eg. Erythrodermic, guttate, or pustular) 2. Have a history of chronic or recurrent infectious disease 3. Have received phototherapy or any systemic medications/treatments within 4 weeks of screening that could affect psoriasis or PASI evaluation 4. Have used topical medications/treatments within 2 weeks of screening that could affect psoriasis or PASI evaluation 5. Have used any systemic immunosuppressants within 4 weeks of screening 6. Have been administered with the following biological agents that could affect plaque-type psoriasis * Etanercept - within 4 weeks of screening * Adalimumab, alefacept, infliximab - within 2 months of screening * Ustekinumab - within 4 weeks of screening * Other investigational biological agents - within 4 weeks of screening/five half-lives(whichever was longer) 7. Pregnant, breast-feeding women or women who plan to become pregnant during this study (Females of childbearing potential must have a negative urine pregnancy test at screening) 8. Have been administered any types of investigational drugs within the previous 4 weeks or five half-lives of the investigational agent, whichever is longer 9. Subject who already took or need to take medicine which is prohibited during the clinical study 10. Subject who has sever dyshepatia (Creatinine value ≥ 2X Upper limit of the normal range at screening test) 11. Subject who has severe renal dysfunction (AST/ALT value ≥ 2X Upper limit of the normal range at screening test) 12. Have received a live viral or bacterial vaccination within 3 months of screening 13. Have had a BCG(Bacillus Calmette-Guérin) vaccination within 12 months of screening 14. Have a transplanted organ(with the exception of a corneal transplant \> 3 months prior to screening) 15. Have any known malignancy or have a history of malignancy 16. Have a history of hypersensitivity, heavy metal poisoning etc. to drugs which are composed of similar components or have undergone allergy immunotherapy previously for prevention of anaphylactic reactions 17. Have had a serious infection (eg. Sepsis, pneumonia or pyelonephritis), or have been hospitalized or received IV antibiotics for an infection during the 2 months prior to screening 18. Positive for Hepatitis B virus(HBV) surface antigen or anti-Hepatitis C virus antibody screening 19. Known to have had a substance abuse(drug or alcohol) problem within 12 months of screening 20. Subject who experienced stem cell therapy 21. Any other conditions which the PI suspect the patient to be unsuitable for the clinical
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of adverse events | 4 weeks follow-up after treatment |
| safety lab tests, physical examination, ECG, vital signs | 4 weeks follow-up after treatment |
| variation of Cytokine, PASI, BSA | 4 weeks follow-up after treatment |
Other
| Measure | Time frame |
|---|---|
| number of adverse events, safety lab tests, physical examination, vital signs | 144 weeks follow-up after treatment (Extension study) |
Countries
South Korea
Contacts
Primary ContactEunji Kang
Outcome results
None listed